The selective expression of NKG2D ligands on tumour exosomes and the inhibition of its receptors on the NK cells was accompanied by a lesser expression of DNAM‐1 ligands and unaffected DNAM‐1 receptor expression suggesting that NKG2D might be a more prominent target for tumour cells (Labani‐Motlagh et al., 2016). The gene discussed is CD226; the disease is neoplasm.